NEW YORK (GenomeWeb News) – Biospecimen firm Sanguine BioSciences announced on Thursday the closing of its seed funding round.

The round was led by Invent Ventures and Heliant Ventures and will be used to further build Sanguine's infrastructure, it said. Sanguine did not disclose the amount of the funding.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.